Runners, cyclists and other fitness enthusiasts say weight-loss drugs give them a performance edge, despite potential risks.

Within Novo Nordisk's comprehensive business update to investors, attention latched onto early data for an oral obesity therapy that outperformed the company’s big-selling GLP-1 agonist Wegovy ...